Large-sized Hepatocellular Carcinoma (HCC): a Neoadjuvant Treatment Protocol with Repetitive Transarterial Chemoembolization (TACE) Before Percutaneous MR-guided Laser-induced Thermotherapy (LITT)
Overview
Authors
Affiliations
This study aims to evaluate the efficacy and safety of a neoadjuvant treatment protocol with repeated transarterial chemoembolization (TACE) before MR-guided laser-induced thermotherapy (LITT) for large-sized hepatocellular carcinomas (HCC). Repeated TACE (mean, 3.5 treatments per patient) was performed in 48 patients with neoadjuvant intention (the largest lesion was between 50 and 80 mm in diameter, and there were no more than five lesions). For the TACE treatment, we used 10 mg/m(2) mitomycin, 10 ml/m(2) Lipiodol and microspheres. The tumor volume was measured by MRI. Lipiodol retention of the tumors was evaluated with CT. After the diameter of the tumors had decreased to less than 50 mm, the patients were treated with MR-guided LITT 4 to 6 weeks after embolization. Repeated TACE reduced the tumor size in 32 patients (66.7%), forming the basis for performing MR-guided LITT procedures. These patients received one to four laser treatments (mean, 1.9 per patient) for tumor ablation, resulting in a median survival of 36.0 months after the first treatment. For the remaining patients, no reduction in tumor size was achieved in 12 patients and disease progression in 4 patients. Neoadjuvant TACE appears to be an effective treatment of large-sized HCC, which extends the indication for MR-guided LITT.
An C, Wu S, Zuo M, Li W, Li K, Wu P Ther Adv Med Oncol. 2025; 17:17588359241306648.
PMID: 39759827 PMC: 11694308. DOI: 10.1177/17588359241306648.
Bench-to-bedside development of multifunctional flexible embolic agents.
Wang D, Rao W Theranostics. 2023; 13(7):2114-2139.
PMID: 37153738 PMC: 10157739. DOI: 10.7150/thno.80213.
Mohr I, Vogeler M, Pfeiffenberger J, Sprengel S, Klauss M, Radeleff B J Cancer Res Clin Oncol. 2022; 148(11):3163-3174.
PMID: 35076764 PMC: 9508038. DOI: 10.1007/s00432-021-03900-3.
Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?.
Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T World J Gastrointest Oncol. 2022; 13(12):1896-1918.
PMID: 35070032 PMC: 8713312. DOI: 10.4251/wjgo.v13.i12.1896.
Qian K, Zhang F, Allison S, Zheng C, Yang X J Interv Med. 2021; 4(1):1-7.
PMID: 34805939 PMC: 8562266. DOI: 10.1016/j.jimed.2020.10.008.